Searched for
ANTIDIABETIC DRUG
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Lupin launches generic anti-diabetic tablets in USPharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Glenmark launches antidiabetic drug in IndiaThe drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the compan...
- Pregnant women can soon take anti-diabetes drug MetforminThe UK and some EU countries allow this drug for pregnant women and during the periconceptional phase. So far, doctors in India prescribe i...
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Mankind pharma joins the anti-diabetic drug warIndia's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...
- Cadila crashes the gliptin market with 'most affordable anti diabetic drug'Tenglyn, is a product belonging to a new class of drugs called gliptins, a segment that has witnessed the most aggressive growth among all ...
- Scientifically validated Rs 5 anti-diabetes herbal drug launched by CSIRThe drug has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medici...
- High Court restrains Glenmark Pharmaceuticals from business of anti-diabetes drugsEarlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...
- Boehringer Igelheim aims for top slot with anti-diabetes drug launchWith Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
- MSD-Glenmark drug patent row: Delhi High Court reserves verdictThe Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.
- No interim relief to Merck against Glenmark’s diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...
- Zydus files IND application with DCGI for diabetes and obesityHealthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...
Load More
